Every earnings call for CONCORDBIO — management tone, guidance, KPIs and promise tracking, quarter by quarter.
CONCORDBIO · 6 transcripts · Healthcare · latest Q3 FY26Revenue ₹278 cr (+14% YoY); EBITDA ₹99 cr (+1% YoY); EBITDA Margin 35.6%. Revenue of ₹278 crores, up 14% YoY.
Read full transcript & analysisRevenue ₹247 cr (−20% YoY); EBITDA ₹88 cr; EBITDA Margin 36%. Revenue for Q2 FY26 stood at ₹247 crores, representing a 20% YoY decline but a 21% QoQ growth.
Read full transcript & analysisRevenue ₹204 cr (−6% YoY); EBITDA ₹61 cr (−25% YoY); EBITDA Margin 30.1%. Revenue stood at ₹204 crores, a 5% YoY decline due to revenue lumpiness and high base in Q4 FY25.
Read full transcript & analysisRevenue ₹1,200 cr (+18% YoY); EBITDA ₹506 cr (+17% YoY); EBITDA Margin 42.2%. Full year FY25 revenue reached ₹1,200 crores, representing 18% YoY growth.
Read full transcript & analysisRevenue ₹244 cr (+2% YoY); EBITDA ₹98 cr (−7% YoY); EBITDA Margin 40.1%. Revenue from operations stood at ₹244 crores, a modest 1% YoY growth, impacted by customer procurement phasing.
Read full transcript & analysisRevenue ₹310 cr (+18% YoY); EBITDA ₹137 cr (+15% YoY); EBITDA Margin 44%. Revenue for Q2 FY25 stood at ₹310 crores, representing an 18% YoY growth.
Read full transcript & analysis